High Dose IL-2 and Stereotactic Ablative Body Radiation Therapy for Metastatic Renal Cancer
Status:
Completed
Trial end date:
2021-04-20
Target enrollment:
Participant gender:
Summary
In this i-SABR (immunotherapy + Stereotactic Ablative Body Radiation) trial, the stereotactic
radiation to multiple metastatic sites is delivered not only to eradicate sites of bulky
progressive disease, but also to provide antigen presentation and immune stimulation which is
expected to act synergistically when immediately followed by the non-specific immune
stimulation provided by treatment with HD IL-2 and thereby increase the response rate and
complete response for metastatic clear cell renal cell cancer patients. Both HD IL-2 and SABR
are FDA approved therapeutic cancer treatment
Phase:
Phase 2
Details
Lead Sponsor:
University of Texas Southwestern Medical Center
Collaborators:
Prometheus Laboratories Prometheus Therapeutics and Diagnostics